SAREPTA THERAPEUTICS, INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- SAREPTA THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $241.00K, a 97.33% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $26.00K, a 99.70% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $1.50M, a 96.24% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-03-31 was $9.04M, a 42.00% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2025 was $10.87M, a 83.85% decline from fiscal 2024.
- SAREPTA THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2024 was $67.32M, a 66.28% increase from fiscal 2023.
- SAREPTA THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2023 was $40.48M, a 79.35% increase from fiscal 2022.
- SAREPTA THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2022 was $22.57M, a 74.13% increase from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-03-31 | $241.00K 10-Q · filed 2026-08-05 | |
| 2025-12-31 | $10.87M 10-K · filed 2026-03-02 | |
| 2025-09-30 | $26.00K 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $1.50M 10-Q · filed 2026-08-05 | |
| 2025-03-31 | $9.04M 10-Q · filed 2026-08-05 | |
| 2024-12-31 | $67.32M 10-K · filed 2026-03-02 | |
| 2024-09-30 | $8.59M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $39.92M 10-Q · filed 2025-11-06 | |
| 2024-03-31 | $15.58M 10-Q · filed 2025-11-06 | |
| 2023-12-31 | $40.48M 10-K · filed 2026-03-02 | |
| 2023-09-30 | $9.87M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $5.86M 10-Q · filed 2024-11-06 | |
| 2023-03-31 | $22.81M 10-Q · filed 2024-11-06 | |
| 2022-12-31 | $22.57M 10-K · filed 2025-02-28 | |
| 2022-09-30 | $9.93M 10-Q · filed 2023-11-01 | |
| 2022-06-30 | $339.00K 10-Q · filed 2023-11-01 | |
| 2022-03-31 | $997.00K 10-Q · filed 2023-11-01 | |
| 2021-12-31 | $12.96M 10-K · filed 2024-02-28 | |
| 2021-09-30 | $2.61M 10-Q · filed 2022-11-02 | |
| 2021-06-30 | $3.53M 10-Q · filed 2022-11-02 | |
| 2021-03-31 | $4.68M 10-Q · filed 2022-11-02 | |
| 2020-12-31 | $76.49M 10-K · filed 2023-02-28 | |
| 2020-09-30 | $15.12M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $21.86M 10-Q · filed 2021-11-03 | |
| 2020-03-31 | $3.69M 10-Q · filed 2021-11-03 | |
| 2019-12-31 | $31.52M 10-K · filed 2022-03-01 | |
| 2019-09-30 | $2.43M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $7.09M 10-Q · filed 2020-11-05 | |
| 2019-03-31 | $9.97M 10-Q · filed 2020-11-05 | |
| 2018-12-31 | $47.92M 10-K · filed 2021-03-01 | |
| 2018-09-30 | $7.09M 10-Q · filed 2019-11-07 | |
| 2018-06-30 | $21.74M 10-Q · filed 2019-11-07 | |
| 2018-03-31 | $11.89M 10-Q · filed 2019-11-07 | |
| 2017-12-31 | $13.80M 10-K · filed 2020-02-26 | |
| 2016-12-31 | $19.35M 10-K · filed 2019-02-28 | |
| 2015-12-31 | $10.01M 10-K · filed 2018-03-01 | |
| 2014-12-31 | $980.00K 10-K · filed 2017-02-28 | |
| 2013-12-31 | $2.73M 10-K · filed 2016-02-25 | |
| 2012-12-31 | $3.78M 10-K · filed 2015-02-26 | |
| 2011-12-31 | $166.00K 10-K · filed 2014-03-03 | |
| 2010-12-31 | $2.01M 10-K · filed 2013-03-15 | |
| 2009-12-31 | $76.00K 10-K · filed 2012-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |